Clinical Trial Update: Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

This update outlines a Phase 2 clinical trial evaluating the combination of SGT-53 with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• SGT-53

Snippet

Sponsor: SynerGene Therapeutics, Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING